Since 2015, three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib have been approved for HR‐positive/HER2‐negative breast cancer in various settings and combination regimens.397, 398. The gene discussed is CDK4; the disease is breast cancer.